| The transcriptional landscape of the mammalian genome P Carninci, T Kasukawa, S Katayama, J Gough, MC Frith, N Maeda, ... science 309 (5740), 1559-1563, 2005 | 4125 | 2005 |
| Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs RIKEN Genome Exploration Research Group Phase I Team: Carninci P. 2 Hayatsu ... Nature 420 (6915), 563-573, 2002 | 2203 | 2002 |
| Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes SA Shukla, MS Rooney, M Rajasagi, G Tiao, PM Dixon, MS Lawrence, ... Nature biotechnology 33 (11), 1152-1158, 2015 | 818 | 2015 |
| Food authentication: Techniques, trends & emerging approaches GP Danezis, AS Tsagkaris, F Camin, V Brusic, CA Georgiou TrAC Trends in Analytical Chemistry 85, 123-132, 2016 | 696 | 2016 |
| Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia M Rajasagi, SA Shukla, EF Fritsch, DB Keskin, D DeLuca, E Carmona, ... Blood 124 (3), 453-462, 2014 | 480 | 2014 |
| Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research HH Lin, S Ray, S Tongchusak, EL Reinherz, V Brusic BMC immunology 9 (1), 8, 2008 | 456 | 2008 |
| Molecular evolution and phylogeny of elapid snake venom three-finger toxins BG Fry, W Wüster, RM Kini, V Brusic, A Khan, D Venkataraman, ... Journal of molecular evolution 57 (1), 110-129, 2003 | 441 | 2003 |
| Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network. V Brusic, G Rudy, G Honeyman, J Hammer, L Harrison Bioinformatics (Oxford, England) 14 (2), 121-130, 1998 | 406 | 1998 |
| HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane ZYJ Sun, KJ Oh, M Kim, J Yu, V Brusic, L Song, Z Qiao, J Wang, ... Immunity 28 (1), 52-63, 2008 | 342 | 2008 |
| MHCPEP, a database of MHC-binding peptides: update 1997 V Brusic, G Rudy, LC Harrison Nucleic acids research 26 (1), 368-371, 1998 | 295 | 1998 |
| HLA-binding properties of tumor neoepitopes in humans EF Fritsch, M Rajasagi, PA Ott, V Brusic, N Hacohen, CJ Wu Cancer immunology research 2 (6), 522-529, 2014 | 257 | 2014 |
| ANTIMIC: a database of antimicrobial sequences M Brahmachary, SPT Krishnan, JLY Koh, AM Khan, SH Seah, TW Tan, ... Nucleic acids research 32 (suppl_1), D586-D589, 2004 | 252 | 2004 |
| Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets AT Heiny, O Miotto, KN Srinivasan, AM Khan, GL Zhang, V Brusic, TW Tan, ... PloS one 2 (11), e1190, 2007 | 246 | 2007 |
| Neural network-based prediction of candidate T-cell epitopes MC Honeyman, V Brusic, NL Stone, LC Harrison Nature biotechnology 16 (10), 966-969, 1998 | 234 | 1998 |
| Computational methods for prediction of T-cell epitopes—a framework for modelling, testing, and applications V Brusic, VB Bajic, N Petrovsky Methods 34 (4), 436-443, 2004 | 230 | 2004 |
| Food authentication: state of the art and prospects GP Danezis, AS Tsagkaris, V Brusic, CA Georgiou Current Opinion in Food Science 10, 22-31, 2016 | 227 | 2016 |
| Melan-A/MART-151–73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4+ T cells HM Zarour, JM Kirkwood, LS Kierstead, W Herr, V Brusic, CL Slingluff Jr, ... Proceedings of the National Academy of Sciences 97 (1), 400-405, 2000 | 205 | 2000 |
| Methods for prediction of peptide binding to MHC molecules: a comparative study K Yu, N Petrovsky, C Schönbach, JLY Koh, V Brusic Molecular medicine 8 (3), 137-148, 2002 | 195 | 2002 |
| MULTIPRED: a computational system for prediction of promiscuous HLA binding peptides GL Zhang, AM Khan, KN Srinivasan, JT August, V Brusic Nucleic acids research 33 (suppl_2), W172-W179, 2005 | 191 | 2005 |
| NY-ESO-1 119–143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1-and Th2-type tumor-reactive CD4+ T cells HM Zarour, B Maillere, V Brusic, K Coval, E Williams, S Pouvelle-Moratille, ... Cancer research 62 (1), 213-218, 2002 | 157 | 2002 |
Guang Lan ZhangCS Department, MET, Boston University; Dana-Farber Cancer Institute, Harvard Medical SchoolVerified email at bu.edu
